5-oxoproline glutathione Pyroglutamic Acidosis • LITFL • CCC Acid-base Metabolic acidosis in late pregnancy

Fast responders, comprising another 30-40% of users, experience meaningful improvement within the first 1-2 weeks

The depletion of glucose in the skin particularly affected the Th1 effector response, because Th1 cells displayed a higher glycolytic score than Th2 cells (Fig

Engage in moderate exercise Regular moderate exercise plays a significant role in maintaining and increasing healthy glutathione levels

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy

Peripheral markers of brain damage and blood-brain barrier dysfunction